Drug Innovations 2007 Sponsors
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and our vital medicines, visit http://www.amgen.com.
PRESENTATION TOPIC - BIOLOGICS (Small Molecule vs. the New Large Molecule Biologic Drugs)
AstraZeneca is a leading global pharmaceutical company
with an extensive product portfolio spanning six major therapeutic
areas: gastrointestinal, cardiovascular, infection, neuroscience, oncology, and respiratory. In Canada, AstraZeneca employs approximately
1,400 employees and its headquarters and packaging facilities are located
in Mississauga, Ontario and a state-of-the-art drug discovery centre
based in Montreal, Quebec. For more information, visit the company’s
website at www.astrazeneca.ca
AstraZeneca est un chef de file mondial de l'industrie pharmaceutique, comme en témoigne son imposante gamme de médicaments dans six domaines thérapeutiques majeurs : gastro-entérologie, cardiologie, infectiologie, neurosciences, oncologie et pneumologie. Le siège social canadien d'AstraZeneca et les installations de conditionnement sont situés à Mississauga, en Ontario, et son centre ultramoderne de
découverte de médicaments est à Montréal, au Québec. Pour de plus amples renseignements, visitez le site Web de la compagnie à www.astrazeneca.ca.
PRESENTATION TOPIC - The Impact of Benefit Plan Design on Cost and Health Outcomes
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb is a leading provider of medicines to fight cancer, cardiovascular and metabolic disorders, infectious diseases (including HIV/AIDS), nervous system diseases and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMY symbol (NYSE:BMY). Bristol-Myers Squibb Canada's operations are headquartered in Montréal, Québec. To visit their website, please go to www.bmscanada.com
PRESENTATION TOPIC: The Current Challenges of Treating HIV
At Merck Frosst, patients come first. Merck Frosst Canada Ltd. is a research-driven pharmaceutical company. Merck Frosst discovers, develops and markets a broad range of innovative medicines to improve human health. The Merck Frosst Centre for Therapeutic Research, one of the largest biomedical research facilities in Canada, has the mandate to discover new therapies for the treatment of respiratory diseases, inflammatory diseases, diabetes and osteoporosis. Merck Frosst is one of the top 20 R&D investors in Canada, with an investment of $117 million in 2005. The Company is committed to fostering partnerships to deliver the most valuable health outcomes for Canadian patients.
Merck Frosst is a recognized leader in the treatment of asthma, osteoporosis, HIV/AIDS, glaucoma, prostate disease, migraines and infectious diseases. The Company also markets an extensive line of cardiovascular products for high blood pressure, elevated cholesterol and heart failure as well as a broad range of vaccines. Based in Montréal, Quebec, Merck Frosst employs nearly 1,600 people including more than 300 of the world’s leading scientific personnel. It is also firmly committed to science education and sponsors a number of programs designed to spark young people’s interest in science. More information about Merck Frosst is available at http://www.merckfrosst.com.
PRESENTATION TOPIC - New emerging diabetes therapies: will they impact the diabetes epidemic?
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, the world's leading pharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals, as well as many of the world's best-known over-the-counter healthcare products. Pfizer Inc invests more than US$7 billion annually in R&D to discover and develop innovative life-saving and life-enhancing medicines in a wide range of therapeutic areas, including arthritis, cardiovascular disease, endocrinology, HIV/AIDS, infectious disease, neurological disease, oncology, ophthalmology and smoking cessation.
Global headquarters are located in New York City, where the company was founded in 1849. During the Second World War, Pfizer became the first company to mass-produce penicillin, launching Pfizer into the modern pharmaceutical era. Pfizer Canada is one of the top investors in Canadian R&D, investing more than $190 million in 2005. Canadian headquarters of Pfizer Global Pharmaceuticals is in Kirkland, Quebec. Pfizer Canada also operates distribution facilities in Ontario and western Canada.
As one of the top corporate charitable donors in Canada, Pfizer Canada is a proud member of Imagine Canada and its Caring Company program. In 2005, Pfizer Canada's Community Investment Program supported more than 1000 non-profit organizations and projects across the country with a total investment exceeding $17 million. For more information, visit www.pfizer.ca.
PRESENTATION TOPIC - Inhaled Insulin: Exhubera - Helping Diabetics Who Require Insulin to Improve Blood Glucose Control
For more information about this event or this webpage, contact Jennifer Minto Assistant Editor, Conferences
|
